Curasight A/S (NGM:CURAS)

Sweden flag Sweden · Delayed Price · Currency is SEK · Price in DKK
2.310
+0.060 (2.67%)
At close: Jul 1, 2025
-81.52%
Market Cap 159.04M
Revenue (ttm) n/a
Net Income (ttm) -49.52M
Shares Out 45.87M
EPS (ttm) -2.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 65,683
Average Volume 218,447
Open 2.380
Previous Close 2.250
Day's Range 2.300 - 2.440
52-Week Range 1.800 - 13.400
Beta 0.03
RSI 44.02
Earnings Date Aug 28, 2025

About Curasight

Curasight A/S, a biotech company, develops treatment of cancer. The company exploits a novel Positron Emissions Tomography (PET) imaging platform that targets the urokinase-type plasminogen activator receptor (uPAR). It develops uTRACE for enhanced evaluation of cancer disease across several cancer types has been confirmed in multiple phase II clinical trials; and uTREAT, a uPAR targeted radionuclide therapy is using uTRACE together with radiation therapy to irradiate cancer with limited irradiation of healthy tissue. The company focuses on gen... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances
Founded 2013
Employees 4
Stock Exchange Nordic Growth Market
Ticker Symbol CURAS
Full Company Profile

Financial Performance

Financial numbers in DKK Financial Statements

News

There is no news available yet.